INTRODUCTION

Lung cancer (LC) is recognized as the commonest cancer type and the predominant cause of tumor-related mortality.\(^1\) Statistics show that about 80% of LC cases are NSCLC.\(^2\) Although recent years have seen the encouraging advances in diagnosis and treatment tools, patients with NSCLC are still faced with unsatisfactory long-term prognosis.\(^3\) Hence, the molecular mechanism research on NSCLC is required to improve the prognosis of NSCLC.

LIM domains-containing 1 (LIMD1) belongs to Ajuba family of LIM domain-containing proteins.\(^4\),\(^5\) A number of studies reveal that deletion of LIMD1 results in aberrant cellular behaviors, such as cell cycle perturbation and hyperproliferation of NSCLC cells.\(^3\) Hence, the molecular mechanism research on LIMD1 is required to improve the prognosis of NSCLC.

Abstract

**Background:** Non-small cell lung cancer (NSCLC) occupies the majority of lung cancer cases and is notorious for the awful prognosis. LIM domains-containing 1 (LIMD1) is suggested as a tumor suppressor in lung cancer, but its mechanism in NSCLC remains elusive. Present study aimed to uncover the mechanism of LIMD1 in NSCLC.

**Methods:** qRT-PCR was performed to analyze the level of LIMD1. The functions of LIMD1 in NSCLC cells were evaluated by CCK-8, EdU, and caspase-3 activity assays. RIP and pull-down assays were applied to determine the interaction of LIMD1 with heterogeneous nuclear ribonucleoprotein U (hnRNP U) and LIMD1-AS1.

**Results:** LIMD1 was downregulated in NSCLC samples and cells. Functionally, LIMD1 hindered proliferation and drove apoptosis in NSCLC cells. Moreover, long noncoding RNA (lncRNA) LIMD1 antisense RNA 1 (LIMD1-AS1) was downregulated in NSCLC samples and cell lines. LIMD1-AS1 knockdown abrogated NSCLC cell growth in vitro and in vivo. Mechanistically, LIMD1-AS1 stabilized LIMD1 mRNA through interacting with hnRNP U. Rescue experiments suggested that LIMD1-AS1 repressed NSCLC progression through LIMD1.

**Conclusions:** LIMD1-AS1 suppressed NSCLC progression through stabilizing LIMD1 mRNA via hnRNP U, providing new thoughts for the improvement of molecular-targeted therapy for NSCLC.

**KEYWORDS**

hnRNP U, LIMD1, LIMD1-AS1, NSCLC
The tumor-suppressive impact of LIMD1 is supported by studies in multiple cancers, such as gastric cancer and cervical cancer. In NSCLC, evidence proves that LIMD1 is downregulated and results in the misregulation of retinoblastoma protein (pRB) and cell cycle. Moreover, overexpression of LIMD1 in A549 lung cancer cell line hinders tumor growth both in vitro and in vivo. However, the how LIMD1 expression is modulated in NSCLC remains elusive.

Long noncoding RNAs (lncRNAs) are the transcripts incapable of translating proteins and are 200 bases long. As documented in numerous studies, they are vital modulators of cancer-related biological activities, including apoptosis, cell growth, invasion, and migration. Also, lncRNAs implicated in NSCLC are reported accumulatively. For example, silencing lncRNA PVT1 inhibits NSCLC development by regulating miR-497. SNHG1 induces NSCLC progression through blocking miR-101-3p and activating Wnt/β-catenin pathway. LIMD1-AS1 is first discovered by our study as an lncRNA nearby LIMD1, and its role in NSCLC is never explained. We are interested in LIMD1-AS1 because antisense RNAs are reported to modulate their nearby genes, which indicates that LIMD1-AS1 potentially modulates LIMD1 in NSCLC.

Heterogeneous nuclear ribonucleoprotein U (hnRNP U), also known as scaffold attachment factor (SAF)-A, participates in the regulation of mRNA transporting and processing. Recent reports show the implication of hnRNP U in modulating DNA damage response and cell apoptosis. In lung cancer, hnRNP U is reported to be downregulated and reduces β-catenin expression by β-TrCP to inhibit lung cancer progression. Notably, hnRNP U is a regulator of mRNA stability. However, the interaction of hnRNP U with LIMD1 and LIMD1-AS1 has not been reported.

The goal of this paper is to demonstrate the influences of LIMD1-AS1 on NSCLC development and to clarify the regulation of LIMD1-AS1 on LIMD1. Mechanistically, RIP assay measured the interaction between LIMD1 mRNA and hnRNPU. Pull-down assay evaluated the interaction between LIMD1-AS1 and LIMD1 mRNA. Function of LIMD1-AS1 was investigated in vitro by CCK-8, EdU, and caspase-3 assays and explored in vivo by establishing xenografts in mice.

2 | MATERIALS AND METHODS

2.1 | Bioinformatics analysis

The downregulation of LIMD1 and LIMD1-AS1 in NSCLC, along with their positive correlation were predicted by GEPIA (http://gepia.cancer-pku.cn/index.html). LIMD1-AS1 was found to be the neighbor gene of LIMD1 via UCSC tool (http://genome.ucsc.edu/). In addition, Starbase (http://starbase.sysu.edu.cn/) predicted that hnRNPU was a (RNA binding protein) RBP of LIMD1.

2.2 | Tissue collection

The NSCLC specimens and matched adjacent normal specimens were dissected from 46 NSCLC patients in the Second People’s Hospital of Hefei, and they all received no other radiotherapy or chemotherapy before. Signed consents were obtained from all patients and experiment procedure was permitted by ethic committee of the Second People's Hospital of Hefei. The specimens collected were immediately stored under −80°C in nitrogen until experiments were unfolded.

2.3 | Cell culture

Human bronchial epithelial cell (16HBE), human NSCLC cells (A549, H1299, H23, and SPC-A1), and human renal epithelial cell (293T) were all attained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). 293T and 16HBE cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; HyClone) with 10% fetal bovine serum (FBS; Thermo Fisher Scientific) plus 1% penicillin–streptomycin antibiotics (HyClone). A549, H1299, H23, and SPC-A1 cells were all grown in RPMI 1640 medium (Invitrogen) containing 10% FBS and 1% antibiotics. All media mentioned above were changed every 3 days. Cells were incubated under a humidified air with 5% CO₂ at 37°C.

2.4 | Cell transfection

SPC-A1 or A549 cells were put into 6-well plates when cell confluence reached 50%-80%. To increase the expression of LIMD1, LIMD1-AS1, or hnRNPU, the pcDNA3.1/LMID1, pcDNA3.1/LIMD1-AS1, and pcDNA3.1/hnRNPU vectors (Genechem) and their corresponding empty vectors were transfected into SPC-A1 or A549 cells. The screen of stable cells transfected with pcDNA3.1/LMID1, pcDNA3.1/LIMD1-AS1, and pcDNA3.1/hnRNPU vectors (Genechem) and their corresponding empty vectors were transfected into SPC-A1 or A549 cells. The screen of stable cells transfected with pcDNA3.1/LMID1, pcDNA3.1/LIMD1-AS1, and pcDNA3.1/hnRNPU was conducted using G418 (Invitrogen Life Technologies). The short hairpin RNAs (shRNAs) against LIMD1 (sh-LIMD1#1: CCGGGATCTACTGTGTCCGAGATTACTCGAGTTATCTCGGACACAGTAGATCTTTTTG, sh-LIMD1#2: CCGGGCCTCACTCATGGAGACTATTCTCGAGATAGTCTCCATGAGTGAGGCTTTTTG), LIMD1-AS1 (sh-LIMD1-AS1#1: GGTTGTACGGAAATGGGTTCC, sh-LIMD1-AS1#2: GCTAACCAACACTGGCTATTA) or HNRNPU (sh-hnRNPU #1: CCGGGGATCTACTGTGTCCGAGATTACTCGAGTTATCTCGGACACAGTAGATCTTTTTG, sh-hnRNPU#2: CCGGGGATCTACTGTGTCCGAGATTACTCGAGTTATCTCGGACACAGTAGATCTTTTTG) was used to silence LIMD1, LIMD1-AS1, and hnRNPU.
AAGCACTGGTTTGG, sh-hnRNP U #2: CCGGGCAACTG
TGAGACTGAAGATTCTCGAGAATCTTCAGTCTCAC
AGTTGCTTTTTG), along with controls (sh-NC), were
constructed simultaneously by Genechem to silence
LIMD1 or LIMD1-AS1 expression. Cell transfection was
performed in line with the specification of Lipofectamine
2000 Reagent (Invitrogen). Transfection lasted 48 hours.

2.5 | Quantitative real-time PCR

SPC-A1 or A549 cells were subjected to total RNA extrac-
tion via a commercially available TRIzol reagent (Invitrogen).
First-strand cDNA was synthesized via reverse transcriptase kit
(Takara). To examine the fluorescence intensity of the ampli-
fied products, the qRT-PCR was accordingly conducted on a
Step One Applied Biosystems (Applied Biosystems) applying
SYBR Green Master (Roche). The reactions were performed as
below: at 55°C for 2 minutes, at 95°C for 10 minutes, then 40
cycles of amplification at 95°C for 15 seconds, and ended with
60°C for 1 minute. Relative gene expression was analyzed by
the 2−ΔΔCt method, while housekeeping gene GAPDH served
as the loading control. Primers are:

|      | LIMD1          | LIMD1-AS1       | hnRNP U       | GAPDH         |
|------|----------------|----------------|---------------|---------------|
|      | 5′-TGGGGAACCTCATTACATGAC-3′ (forward) | 5′-TAGGGGTGAGGGGTAAGTGG-3′ (forward) | 5′-GAGCATCCTATGTTGTTCAAA-3′ (forward) | 5′-GGGAGCCAAAAGGGTCAT-3′ (forward) |
|      | 5′-CACA AAAACACTTTGCCGTTG-3′ (reverse) | 5′-CTTCATGCCAGAAACTGCTCT-3′ (reverse) | 5′-TGACCA GCAATA CGA AACTTC-3′ (reverse) | 5′-GATC CTTCCACGATACCAA-3′ (reverse) |

2.6 | Cell viability assay

SPC-A1 or A549 cells were reaped after transfection and
seeded into 96-well plates when cell density reached 2000
cells per well. Cell Counting Kit-8 solution (CCK-8; Dojindo)
without FBS was added to each well after 24, 48, 72, and
96 hours. Absorbance was examined at 450 nm wavelength
via a microplate reader (Bio-Tek Instruments).

2.7 | Caspase-3 activity assay

SPC-A1 or A549 cells were added with 1 mL phosphate
buffer saline (PBS; Thermo Fisher Scientific). Cells were cen-
trifuged for 10 minutes at 4°C after homogenization. Pellets
were cultivated in lysis buffer (Beyotime). Caspase-3 activ-
ity assay was carried out in 96-well plates with lystate, assay
buffer, and Caspase-3 colorimetric substrate Ac-DEVD-pNA
at 37°C for 2 hours. The chromospheres pNA was cleaved
from the substrate molecule. The absorbance values were
measured at a wavelength of 405 nm.

2.8 | Flow cytometry apoptosis assay

After 48 hours of indicated transfections, collected cells were
subjected to a FITC-Annexin V Apoptosis Detection Kit (BD
Biosciences) for analysis following manufacturer’s recommen-
dation. For double staining of cells, FITC-Annexin V as well as
propidium iodide (PI) was used. Then, the apoptosis was ana-
lized by flow cytometry (FACScan; BD Biosciences) and the
CellQuest software (BD Biosciences). Cells that were viable,
early/late apoptotic, or dead were divided, and apoptosis ratio
was considered as the percentage of early/late apoptotic ones.

2.9 | EdU staining

EdU staining was carried out to evaluate the proliferative
capacity. The Click-iT Alexa Fluor 488 Imaging Kit
(Invitrogen) was utilized in accordance with the standard
method. Transfected SPC-A1 or A549 cells were initially
rinsed with 3% bovine serum albumin (BSA; Sigma-Aldrich,
Burlington, Massachusetts, USA) twice and then treated with
150 μL EdU-Click reaction-mix at 20°C for 30 minutes, fol-
lowed by washing with 3% BSA. Cell nuclei were treated
with DAPI staining in the dark.

2.10 | Animal xenografts

Twelve 4-week-old athymic BALB/c nude mice (female)
obtained from Shanghai Laboratory Animal Center were
kept in three disposable plastic cages (n = 4 mice per cage)
under pathogen-free conditions with Sani-Chip bedding.
Before being utilized, the mice were housed in cages for
7 days to accommodate the environment. SPC-A1 cells
were stably transfected with pcDNA3.1/LIMD1-AS1 (ex-
perimental group, n = 6) and pcDNA3.1 empty vector
(control group, n = 6), and collected from 6-well cell cul-
ture plates. After that, cells were washed using phosphate-
buffered saline, followed by cell resuspension. Stably
expressed cells after transfection were subcutaneously in-
jected into both sides of each mouse. Every 3 days, tumor
growth (primary outcome assessed) was monitored and the
equation \( V = 0.5 \times D \times d^2 \) (V, volume; d, latitudinal diam-
eter D; longitudinal diameter) was used for tumor volume
calculation (secondary outcome assessed). Twenty-eight
days’ postinjection, isoflurane anesthesia overdose inha-
lation was applied to euthanized mice, and subcutaneous
tumor growth obtained from euthanized mice underwent


further examination. Following the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, this study was conducted. The researchers who monitored and recorded cell growth were unaware of the accommodation and injection condition of mice.

2.11 | Immunohistochemical staining

To test Ki-67 level, tissue samples were stained. Primary monoclonal probes for Ki-67 were used for tumor detection at 4°C overnight. After that, a suitable second antibody was used for incubation. Tissues underwent diaminobenzidine treatment and hematoxylin counterstaining. A microscope (Carl Zeiss) was applied for tissue observation.

2.12 | Luciferase reporter assay

LIMD1 promoter was cloned into the pGL3-basic to produce pGL3-LIMD1 reporter. 293T cells were co-transfected with the pGL3-LIMD1 vector and pcDNA3.1/LIMD1-AS1 or sh-LIMD1-AS1#1/2, together with their respective controls. Transfection was carried out using Lipofectamine 2000 as per the supplier’s recommendation. The Dual Luciferase Reporter Assay System (Promega) was applied after 48 hours transfection as the manufacturer’s directions requested.

2.13 | RIP assay

According to the protocol of EZ-Magna RIP kit (Millipore), RIP assay was carried out in SPC-A1 and A549 cells. Cell lysates in RIP buffer were treated with magnetic beads conjugated to antibodies against hnRNP U, IgG as negative control or SNRNP70 as positive control. After treatment with proteinase K (Absin), qRT-PCR was performed.

2.14 | Western blotting analysis

To extract protein, RIPA lysis buffer (Solarbio) was applied. Protein was subsequently quantified via BCA protein assay (Beyotime). The separation of protein was performed on 15% SDS-PAGE gels. Protein was shifted to PVDF membranes (Millipore) afterwards. Then, the membranes were blocked by 5% non-fat milk in TBST at room temperature for 1 hour and treated with the primary antibodies, namely, anti-LIMD1 (1/1500, ab155788, Abcam), anti-hnRNP U (1-5 μg/mL, SAB1402227, Sigma-Aldrich) and anti-GAPDH (1/1000, ab8245, Abcam) as an endogenous control. Before incubating with secondary antibodies, the membranes were rinsed with TBST for three times. The ECL system (Santa Cruz Biotechnology) was utilized to monitor the final protein bands.

2.15 | RNA pull-down assay

Plasmids containing LIMD1-AS1 and antisense LIMD1-AS1 sequences were linearly cut, transcribed and biotinylated in vitro for 48 hours using a MAXIscript T7 Transcription Kit (Thermo Fisher Scientific). RNA pull-down assay was conducted using Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific) in A549 cell lysates. The streptavidin-coated magnetic beads (Ambion) were added in the cell lysates, following digestion with proteinase K. The pull-down proteins were subjected to western blot and qRT-PCR.

2.16 | Actinomycin D (Act D) treatment

After transfection, A549 cells were collected and planted in the 6-well plates. 20 μg/mL Act D was incubated with cells to block mRNA transcription. At the indicated time points, cells were harvested. Total RNA was isolated to detect the mRNA stability.

2.17 | Statistical analysis

Statistical analysis was carried out by SPSS 23.0 (SPSS Inc). Each experiment was conducted for at least three times in this research. The Student’s t test or one-way analysis of variance (ANOVA) was used for differences analysis. A value of $P < .05$ was regarded to manifest a statistically significant difference. Results in this research were shown as mean ± standard deviation (SD).

3 | RESULTS

3.1 | LIMD1 was low expressed in NSCLC, and its overexpression hindered proliferation and drove apoptosis of NSCLC cells

To establish association between LIMD1 and NSCLC, we determined LIMD1 expression. By analyzing TCGA data using GEPIA (http://gepia.cancer-pku.cn/), we obtained the downregulation of LIMD1 in lung adenocarcinoma (LUAD) samples compared with the normal samples (Figure 1A). Consistently, LIMD1 was also downregulated in specimens from NSCLC patients (Figure 1B). Besides, we observed the low LIMD1 level in NSCLC cell lines (A549, H1299, H23, and SPC-AS1) versus the normal 16HBE cells (Figure 1C). Thus, we indicated that LIMD1 participated in NSCLC.
Next, impact of LIMD1 in NSCLC was tested in vitro. We overexpressed LIMD1 in SPC-A1 which exhibited the lowest LIMD1 level, and silenced LIMD1 in A549 which exhibited the highest LIMD1 level. qRT-PCR analysis confirmed the elevation of LIMD1 level SCP-A1 cells under pcDNA3.1/LIMD1 transfection and the decline of LIMD1 level in A549 cells under sh-LIMD1#1/2/3 transfection, and sh-LIMD1#1/2 exhibited better knockdown efficiency (Figure S1A). The
EdU-labeled SPC-A1 cells and colonies from SPC-A1 cells were decreased upon LIMD1 overexpression, and opposite result were observed in A549 cells with LIMD1 silence (Figure 1D,E). The caspase-3 activity in SPC-A1 cells increased responding to LIMD1 overexpression, whereas that in A549 cells decreased under LIMD1 silence (Figure 1F). Additionally, apoptotic SPC-A1 cells presented an increased ratio under LIMD1 overexpression, and apoptotic A549 cells exhibited a decreased ratio under LIMD1 silence (Figure 1G). Therefore, LIMD1 functioned as a suppressor in NSCLC by abrogating proliferation and strengthening apoptosis.

3.2 | LIMD1-AS1 was downregulated in NSCLC and positively regulated LIMD1 by stabilizing its mRNA

Thereafter, we investigated the upstream mechanism of LIMD1 in NSCLC. Through browsing UCSC (http://genome.ucsc.edu/), we discovered that the genomic location of LIMD1-AS1 neighbored LIMD1 (Figure 2A). It has been reported that antisense RNAs could potentially regulate the expression of their neighbor genes.18,28 Therefore, we assumed the correlation between LIMD1 and LIMD1-AS1. First, we interrogated the implication of LIMD1-AS1 in NSCLC. According to TCGA data analysis in GEPIA, LIMD1-AS1 level was LOW in LUAD samples (Figure 2B). qRT-PCR data exhibited the suppressed LIMD1-AS1 level in NSCLC specimens versus para-tumor ones (Figure 2C). We also validated the downregulation of LIMD1-AS1 in NSCLC cell lines (Figure 2D). Moreover, we validated positive correlation between LIMD1-AS1 and LIMD1 in LUAD through GEPIA (Figure S1B), and confirmed their positive association in NSCLC tissues (Figure 2E).

Then, the regulation of LIMD1-AS1 on LIMD1 was investigated. We induced LIMD1-AS1 level in SPC-A1 cells and silenced endogenous LIMD1-AS1 expression in A549 cells (Figure S1C). It turned out that level of LIMD1 mRNA and protein increased under LIMD1-AS1 overexpression, but declined under LIMD1-AS1 knockdown (Figure 2F). Regulatory mechanisms of lncRNAs at transcriptional and posttranscriptional levels are extensively reported.29 Hence, we further detected at which level LIMD1-AS1 modulated LIMD1 expression. We discovered that luciferase activity of LIMD1 promoter was not altered under either overexpression or depletion of LIMD1-AS1 (Figure 2G), indicating that LIMD1-AS1 regulated LIMD1 posttranscriptionally. Therefore, we tested whether LIMD1-AS1 affected LIMD1 mRNA stability. After adding Act D to block mRNA synthesis, the remaining LIMD1 mRNA level of was detected by qRT-PCR. Consequently, the mRNA stability of LIMD1 was abrogated by LIMD1-AS1 silence (Figure 2H). Furthermore, LIMD1 protein content increased when LIMD1-AS1 was overexpressed, and declined upon LIMD1-AS1 depletion (Figure 2I).

Additionally, function of LIMD1-AS1 was tested in vivo. Results indicated that SPC-A1 cells with LIMD1-AS1 overexpression formed smaller tumors in mice than control group (Figure S2A). The volume of tumors derived from LIMD1-AS1 overexpressing cells (n = 6) were smaller than that derived from control cells (n = 6) (Figure S2B). The tumor weight in LIMD1-AS1 overexpressing group (x̄ = 301, s = 33) was lighter than that in control group (x̄ = 622, s = 64) (Figure S2C). Immunohistochemical staining also exhibited the reduced positivity of Ki-67 in LIMD1-AS1 overexpression group in comparison to control group (Figure S2D). Collectively, these data implied that LIMD1-AS1 was downregulated in NSCLC and positively regulated LIMD1 by stabilizing its mRNA. Besides, LIMD1-AS1 overexpression impeded tumorigenesis in NSCLC.

3.3 | LIMD1-AS1 stabilized LIMD1 mRNA by interacting with hnRNP U

Furthermore, we asked how LIMD1-AS1 regulated LIMD1 mRNA stability. Mounting reports support that lncRNAs strengthen or impair the mRNA stability through recruiting certain RNA binding proteins (RBPs), including in NSCLC.24 Therefore, we hypothesized that LIMD1-AS1 modulated LIMD1 mRNA stability in this manner. We searched starBase 3.0 (http://starbase.sysu.edu.cn/) to identify the potential RBPs targeting LIMD1, finding that hnRNP U potentially interacted with LIMD1 (Figure 3A). Previous studies report the function of hnRNP U as an mRNA stabilizer.24,26,27 Also, some works prove that hnRNP U exerts suppressive effect on NSCLC progression.24,25 Therefore, we speculated that LIMD1-AS1 regulated LIMD1 mRNA stability through hnRNP U. We confirmed the downregulated hnRNP U level in NSCLC cell lines (Figure 3B). qRT-PCR verified the abundant expression of LIMD1 mRNA in the RIP precipitates of hnRNP U antibody (Figure 3C). Later, we detected the impact of hnRNP U on LIMD1. We silenced hnRNP U expression in A549 cells and confirmed the knockdown efficiency (Figure 3D). Then, we observed that knockdown of hnRNP U reduced the level of LIMD1 mRNA and protein in A549 cells (Figure 3E). Moreover, the half-life of LIMD1 mRNA was shortened by hnRNP U silence (Figure 3F). Further, the interaction between hnRNP U and LIMD1-AS1 was investigated. Pull-down assay revealed that the protein of hnRNP U was enriched in products pulled down by LIMD1-AS1 rather than antisense LIMD1-AS1 (Figure 3G). Also, we confirmed the enrichment of LIMD1 mRNA in the pull-down of LIMD1-AS1 rather than antisense LIMD1-AS1, and that the addition of proteinase K markedly reduced the enrichment (Figure 3H),
indicating that LIMD1-AS1 interacted with LIMD1 in an hnRNP U-required way. Additionally, the overexpression of hnRNP U restored LIMD1 mRNA and protein levels in LIMD1-AS1-silenced A549 cells (Figure 3I). In sum, LIMD1-AS1 stabilized LIMD1 mRNA by interacting with hnRNP U.
Finally, we examined whether LIMD1 mediated the impact of LIMD1-AS1 on NSCLC progression. We validated that LIMD1 expression reduced by LIMD1-AS1 was recovered by transfecting pcDNA3.1/LIMD1 into A549 cells (Figure 4A). CCK-8 and EdU analyses depicted that silencing LIMD1-AS1 facilitated proliferation of A549 cells, and overexpressing LIMD1 abrogated the facilitating effect of LIMD1-AS1 on NSCLC progression.

FIGURE 3 LIMD1-AS1 stabilized LIMD1 mRNA by interacting with hnRNP U. A, Potential interaction between hnRNP U and LIMD1 mRNA was predicted by starBase 3.0. B, qRT-PCR analysis of hnRNP U level in non-small cell lung cancer cell lines versus the normal cell line. C, qRT-PCR analysis of LIMD1 mRNA enrichment in RIP hnRNP U, SNRNP7 and U1 were positive control. D, The knockdown of hnRNP U was examined by qRT-PCR analysis in A549 cells. E, qRT-PCR of LIMD1 mRNA and western blot of LIMD1 protein in A549 cells with hnRNP U silence. F, The level of remaining LIMD1 mRNA was evaluated by qRT-PCR every 2 h after Act D treatment in A549 cells with hnRNP U silence. G, Western blot of hnRNP U in products pulled down by LIMD1-AS1 and antisense LIMD1-AS1. H, qRT-PCR data of LIMD1 mRNA in the pull-down of LIMD1-AS1 and antisense LIMD1-AS1 group in A549 cells treated with Proteinase K (to digest proteins) or with DMSO control. I, qRT-PCR and western blot of LIMD1 level in A549 cells transfected with sh-NC, sh-LIMD1-AS1#1, or sh-LIMD1-AS1#1 + pcDNA3.1/hnRNP U, respectively. *P < .05, **P < .01
of LIMD1-AS1 knockdown (Figure 4B,C). LIMD1-AS1 knockdown impaired caspase-3 activity in A549 cells but the ectopic LIMD1 expression restored caspase-3 activity versus sh-LIMD1-AS1#1 group (Figure 4D). Moreover, overexpressing LIMD1 restored the percentage of apoptotic A549 cells reduced by sh-LIMD1-AS1#1 (Figure 4E). Thus, LIMD1-AS1 impeded proliferation and prompted apoptosis through LIMD1 in NSCLC.

4 | DISCUSSION

Previous studies have suggested that LIMD1 participates in tumor progression of diverse cancers by serving as a tumor-suppressor, such as in gastric cancer and cervical cancer.\(^7,8\) Also, LIMD1 is revealed by former studies to present low expression and hinder tumor growth In NSCLC.\(^9,10\) These findings indicated that the investigating LIMD1-related...
mechanism in NSCLC progression might be helpful to provide new thoughts for molecular-targeted treatments of NSCLC.

In concordance, we confirmed that LIMD1 was downregulated in LUAD samples according to TCGA data analysis and confirmed its low expression in NSCLC specimens and cells according to qRT-PCR data. Functionally, we illustrated that LIMD1 inhibited proliferation and drove apoptosis in NSCLC cells, which was also consistent with previous reports.

As suggested by numerous studies over the past decades, lncRNAs are catching more and more attentions of researchers for their rising roles in cancer progression. A number of lncRNAs have been revealed as promising biological markers in NSCLC, such as lncRNA PVT1 and SNHG1. Our study first discovered lncRNA LIMD1-AS1 in cancer progression. We speculated the modulatory function of LIMD1-AS1 on LIMD1 in NSCLC because former findings imply that lncRNAs could regulate their neighbor genes. We found through UCSC that LIMD1-AS1 was neighbor to LIMD1 according to its genomic location. Through GEPIA, we first uncovered that LIMD1-AS1 was downregulated and positively correlated with LIMD1 expression in LUAD samples. We then confirmed that LIMD1-AS1 positively regulated LIMD1 expression in NSCLC cells at posttranscriptional level by stabilizing LIMD1 mRNA. Additionally, we offered the first data that LIMD1-AS1 overexpression impaired NSCLC tumorigenesis in vivo, suggesting LIMD1-AS1 as an antitumor lncRNA.

Mechanistically, lncRNAs are proved by former studies to interact with RBPs to regulate gene expression. hnRNP U, recognized as a regulator of mRNA transporting and processing, was previously reported to perform suppressive roles in cancers by regulating DNA damage response and cell apoptosis. Interestingly, a study has shown that lncRNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity by stabilizing GADD45A through hnRNP U in lung squamous cell carcinoma. Accordingly, our study confirmed that hnRNP U was downregulated in NSCLC cells. Importantly, we first demonstrated that LIMD1-AS1 interacted with hnRNP U to stabilize LIMD1 mRNA. Finally, we suggested through rescue assay that LIMD1 was involved in the negative regulation of LIMD1-AS1 on NSCLC progression.

One major limitation of our work lies in the sex of the mice utilized in the animal assays. The differences between female and male mice may lead to some unknown random errors, which would be improved in further studies. Also, further research is needed to confirm the functions of LIMD1-AS1 on human NSCLC cells growth.

Taken together, our study first revealed that LIMD1-AS1 suppressed NSCLC progression through stabilizing LIMD1 mRNA via hnRNP U, indicating LIMD1-AS1 as a novel tumor-suppressor gene in NSCLC progression from in vitro and in vivo analyses.

ACKNOWLEDGMENT
The authors thank everyone who participated in this study.

CONFLICT OF INTEREST
The authors declare that they have no competing interests.

AUTHORS’ CONTRIBUTIONS
Conception and design: PJ and TY; Experimentation: PJ and TY; Analysis of data: PJ, TY, LS, LL, and YB; Manuscript the article: LY and WY; Revision and Edition the article: PJ, TY; All authors read and approved the final version of the manuscript.

ETHICAL APPROVAL
Ethical approval was obtained from committee of the Ethics of Animal Experiments of the Second People’s Hospital of Hefei. All procedure regarding animal treatments and the whole study were performed in line with the ethical standards of this committee.

DATA AVAILABILITY STATEMENT
Research data are not shared.

ORCID
Jianyuan Pan https://orcid.org/0000-0001-8188-6824

REFERENCES
1. Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nature Rev Dis Primers. 2015;1:15009.
2. Herbst RS, Heymach JV, Lippman SM. Lung Cancer. N Engl J Med. 2008;359(13):1367-1380.
3. Cheang S, Brown K. Lung cancer staging: clinical and radiologic perspectives. Semin Intervent Radiol. 2013;30(2):99-113.
4. Bach I. The LIM domain: regulation by association. Mech Dev. 2000;91(1):5-17.
5. Kiss H, Kedra D, Yang Y, et al. A novel gene containing LIM domains (LIMD1) is located within the common eliminated region 1 (C3CER1) in 3p21.3. Hum Genet. 1999;105(6):552-559.
6. Huggins CJ, Andrulis IL. Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers. Cancer Lett. 2008;267(1):55-66.
7. Zhang D, Li S, Yu W, et al. LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1. Cancer Management Res. 2018;10:4349-4361.
8. Chakraborty C, Mitra S, Roychowdhury A, et al. Deregulation of LIMD1–VHL–HIF-1α–VEGF pathway is associated with different stages of cervical cancer. Biochem J. 2018;475(10):1793-1806.
9. Sharp TV, Munoz F, Bourboulia D, et al. LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc Nat Acad Sci USA. 2004;101(47):16531-16536.
10. Sharp TV, Al-Attar A, Foxler DE, et al. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Nat Acad Sci USA. 2008;105(50):19932-19937.
11. Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol. 2011;22(4):366-376.
12. Delás MJ, Hannon GJ. IncRNAs in development and disease: from functions to mechanisms. Open Biology. 2017;7(7):170121.
13. Chen C, Zhou L, Wang H, et al. Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. American J Cancer Res. 2018;8(1):192-206.
14. Chen D, Hu C, Wen G, Yang Q, Zhang C, Yang H. DownRegulated SOX4 expression suppresses cell proliferation, migration, and induces apoptosis in osteosarcoma in vitro and in vivo. Calcif Tissue Int. 2018;102(1):117-127.
15. Cheng R, Li N, Yang S, Liu L, Han S. Long non-coding RNA ZEB1-AS1 promotes cell invasion and epithelial to mesenchymal transition through inducing ZEB1 expression in cervical cancer. Oncotargets and therapy. 2018;11:7245-7253.
16. Guo D, Wang Y, Ren K, Han X. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression. Exp Cell Res. 2018;362(1):172-179.
17. Cui Y, Zhang F, Zhu C, Geng L, Tian T, Liu H. Upregulated IncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 2017.
18. Wang A, Bao YI, Wu Z, et al. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer. Cell death. & disease. 2019;10(3):154.
19. Xiao R, Tang P, Yang BO, et al. Nuclear matrix factor hnRNP U/Sen-7C protein inhibits tumor metastasis via the N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung cancer. Oncotarget. 2015;6(42):44207-44221.
20. Lu Y, Liu XU, Xie M, et al. The NF-κB-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. J Immunol. 2012;188(7):3179-3187.
21. Berglund FM, Clarke PR. hnRNP-U is a specific DNA-dependent protein kinase substrate phosphorylated in response to DNA double-strand breaks. Biochem Biophys Res Comm. 2009;381(1):59-64.
22. Li L, Yin J-Y, He F-Z, et al. Long noncoding RNA SFTA1P promoted apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget. 2017;8(57):97476-97489.
23. Tseng R-C, Chang J-W, Mao J-S, et al. Growth-arrest-specific 7C protein inhibits tumor metastasis via the N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung cancer. Oncotarget. 2015;6(42):44207-44221.
24. Fackelmayer FO, Richter A. hnRNP-U/SAF-A is encoded by two differentially polyadenylated mRNAs in human cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1994;1217(2):232-234.
25. Yuami M, Kabe Y, Yamaguchi Y, Wada T, Handa H. hnRNP-U enhances the expression of specific genes by stabilizing mRNA. FEBS Lett. 2007;581(1):1-7.
26. Göhring F, Schwab BL, Nicotera P, Leist M, Fackemayer FO. The novel SAR-binding domain of scaffold attachment factor A (SAF-A) is a target in apoptotic nuclear breakdown. EMBO J. 1997;16(24):7361-7371.
27. Zheng R, Chang J-W, Mao J-S, et al. Long noncoding RNA SFTA1P promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. American J Cancer Res. 2018;8(1):192-206.
28. Cheng R, Li N, Yang S, Liu L, Han S. Long non-coding RNA ZEB1-AS1 promotes cell invasion and epithelial to mesenchymal transition through inducing ZEB1 expression in cervical cancer. Oncotargets and therapy. 2018;11:7245-7253.
29. Guo D, Wang Y, Ren K, Han X. Knockdown of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer by regulating miR-497 expression. Exp Cell Res. 2018;362(1):172-179.
30. Cui Y, Zhang F, Zhu C, Geng L, Tian T, Liu H. Upregulated IncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 2017.
31. Wang A, Bao YI, Wu Z, et al. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer. Cell death. & disease. 2019;10(3):154.
32. Xiao R, Tang P, Yang BO, et al. Nuclear matrix factor hnRNP U/Sen-7C protein inhibits tumor metastasis via the N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung cancer. Oncotarget. 2015;6(42):44207-44221.
33. Fackelmayer FO, Richter A. hnRNP-U/SAF-A is encoded by two differentially polyadenylated mRNAs in human cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1994;1217(2):232-234.
34. Yuami M, Kabe Y, Yamaguchi Y, Wada T, Handa H. hnRNP-U enhances the expression of specific genes by stabilizing mRNA. FEBS Lett. 2007;581(1):1-7.
35. Göhring F, Schwab BL, Nicotera P, Leist M, Fackemayer FO. The novel SAR-binding domain of scaffold attachment factor A (SAF-A) is a target in apoptotic nuclear breakdown. EMBO J. 1997;16(24):7361-7371.
23. Berglund FM, Clarke PR. hnRNP-U is a specific DNA-dependent protein kinase substrate phosphorylated in response to DNA double-strand breaks. Biochem Biophys Res Comm. 2009;381(1):59-64.
24. Li L, Yin J-Y, He F-Z, et al. Long noncoding RNA SFTA1P promotes apoptosis and increased cisplatin chemosensitivity via regulating the hnRNP-U-GADD45A axis in lung squamous cell carcinoma. Oncotarget. 2017;8(57):97476-97489.
25. Tseng R-C, Chang J-W, Mao J-S, et al. Growth-arrest-specific 7C protein inhibits tumor metastasis via the N-WASP/FAK/F-actin and hnRNP U/β-TrCP/β-catenin pathways in lung cancer. Oncotarget. 2015;6(42):44207-44221.
26. Lu Y, Liu XU, Xie M, et al. The NF-κB-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. J Immunol. 2012;188(7):3179-3187.
27. Zhao W, Wang L, Zhang M, et al. Nuclear to cytoplasmic translocation of heterogeneous nuclear ribonucleoprotein U enhances TLR-induced proinflammatory cytokine production by stabilizing mRNAs in macrophages. J Immunol. 2012;188(7):3179-3187.
28. Guo Y, Ma Y, Hu X, Song R, Zhu L, Zhong M. Long non-coding RNA CEBPA-AS1 correlates with poor prognosis and promotes tumorigenesis via CEBPA/Bcl2 in oral squamous cell carcinoma. Cancer Biol Ther. 2018;19(3):205-213.
29. Botti G, Scognamiglio G, Aquino G, Liguori G, Cantile M. LncRNA HOTAIR in Tumor Microenvironment: What Role? Int J Mol Sci. 2019;20(9):2279.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Pan J, Tang Y, Liu S, et al. LIMD1-AS1 suppressed non-small cell lung cancer progression through stabilizing LIMD1 mRNA via hnRNP U. Cancer Med. 2020;9:3829–3839. https://doi.org/10.1002/cam4.2898